Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Dollar Rises as Strait of Hormuz Crisis Pushes Oil Prices Higher 
Gold Prices Hold Firm as Traders Watch U.S.-Iran Ceasefire and Trump-Xi Talks 
Asian Stocks Slip as Korea’s KOSPI Tumbles Amid Iran Conflict and Chip Sector Profit-Taking 
U.S. Army Soldier Charged in $400K Insider Betting Scheme on Maduro Capture 
China Inflation Jumps as Iran Conflict Drives Energy Costs Higher 
Arcadia Mayor Eileen Wang Pleads Guilty in China Foreign Agent Case 
Trump-Iran Tensions Keep Oil Prices Elevated Amid Hormuz Supply Fears 
Asian Currencies Slide as Indian Rupee Hits Record Low Amid Iran Tensions 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Trump DOJ Challenges Colorado’s Large-Capacity Magazine Ban in Second Amendment Lawsuit 
Trump Says Iran Ceasefire Near Collapse as Oil Prices Surge 
Trump Says Iran Ceasefire ‘On Life Support’ as Oil Prices Surge Above $104 
US Trade Court Blocks Trump’s 10% Global Tariffs 
DOJ Ends Probe Into Fed Chair Jerome Powell, Boosting Kevin Warsh Confirmation Prospects 
Trump-Xi Summit Sparks Renewed Hope for Americans Detained in China 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
